• Fish oil preparations have no effect

    The results of the ASCEND study published at the ESC Congress 2018 and in the New England Journal of Medicine show what many have always suspected: Fish oil preparations have absolutely no effect on patients with diabetes. According to Professor Louise Bowman, there is no justification for recommending fish oil preparations to protect against cardiovascular events. A reconsideration of the European Guidelines in this respect should, therefore, be considered.

  • Advances in anticoagulation in patients with atrial fibrillation

    Atrial fibrillation (A-fib) is one of the main risk factors for stroke. For a long time, vitamin K antagonists (VKA) such as warfarin were the drugs of choice in anticoagulation therapy for A-fib. Today, however, the ESC guideline recommends new oral anticoagulants (NOAC) for patients with A-fib in the majority of cases.

  • Blood pressure measurements - But how?

    In the year 2018, the ESC again asked - even more than ever - the question of the right method for measuring blood pressure. Meanwhile, there are many different electronic, automatic and semi-automatic blood pressure monitors in addition to the classic type.

  • Aspirin: Heartbeat versus Bleeding

    Whether aspirin should be used to prevent a cardiovascular event remains uncertain. According to the latest studies, the advantages of avoiding severe vascular events are largely offset by the increased risk of bleeding.

  • esanum Interview: All patients over 65 for cognitive impairment should be examined

    Prof. Freek W. A. Verheugt in an interview at the ESC 2018 on the influence of mental status on the treatment success of older cardiology patients.

  • esanum Interview: Supplementation with omega-3 fatty acids needs to be reconsidered

    Louise Bowman in an interview at the ESC 2018 on the need for a revised version of the guideline recommendations on the supplementation of omega-3 fatty acids.

  • esanum Interview: Improvement of cardiovascular risk factors

    To date, no pharmacological agent to support weight loss has convincingly demonstrated cardiovascular safety in a rigorous clinical trial, said Erin A. Bohula May in an esanum interview during the ESC 2018.

  • Developments in heart medicine affect millions of people

    From 25 to 29 August 2018, 31,000 participants from 150 countries are expected at the European Cardiology Congress in Munich, making the Congress of the European Society of Cardiology (ESC) one of the world's largest medical congresses.

  • Immuno-oncology: universally applicable or age-dependent?

    Immuno-oncology has been groundbreaking and provided patients with more valuable months of life. However, response rates still remain low at around 25%, and immunotherapy success in relation to age needs further research.

  • Rising temperatures and suicide

    New levels of heat may cause between 9,000 to 40,000 more suicides in the US and Mexico

  • Pneumonia in the emergency room: making smarter decisions

    Emergency rooms may be often overwhelmed, and in the heat of the moment, it is important to keep a cool head and yet be open to new recommendations that can help us make wise decisions.

  • WhatsAppitis: watch out for smartphone abuse

    Some medical experts are seeing a rise in cases. In this uncommon phenomenon, thumbs and wrists are overstretched for writing messages, causing sharp pain.

  • Artificial meat is coming soon

    Mosa Meat, a Dutch-based start-up, is creating the first non-animal meat, fully produced in a laboratory.

  • Vitamin D deficiency could be a risk factor for Interstitial Lung Disease (ILD)

    A 10-year long observational study finds a link between low levels of Vitamin D and an increased incidence of inflammatory diseases of the lung including ILD

  • The lower, the better? - Extremely low LDL values in CHD prevention

    With the availability of the new PCSK9 inhibitors Alirocumab and Evolocumab, LDL values can be reduced to below 20 mg/dl for the first time. What is the advantage of such low values? Are patients at risk? A new study provides information.

  • What are human papilloma viruses, and are all HPV types dangerous?

    Human papillomaviruses play an important role in the development of genital warts and the far more dangerous cervical carcinoma. There are well over 140 different HPV types, of which around 40 can infect the anogenital region.

  • New findings on the clinical benefit ustekinumab for patients with SLE

    Safety was as expected based on earlier experience with the agent in psoriasis, psoriatic arthritis (PsA), and Crohn’s disease (CD). Based on these results, ustekinumab may have the potential to offer a new treatment option for patients with SLE.

  • The importance of vitamin A for the intestinal immune system

    The intestinal immune system must constantly maintain the difficult balance between fighting infections and simultaneously tolerating harmless or useful germs, and our food components.

  • Long-term safety profile of adalimumab across indications confirmed

    A recent data analysis of 78 clinical trials of adalimumab demonstrated an overall safety profile consistent with previous findings and the tumor necrosis factor (TNF) inhibitor class.

  • Counteracting insulin resistance with metformin

    There are many type 1 diabetes patients who, despite insulin therapy, have poor metabolic control and high HbA1c values. This is often due to increased insulin resistance, which requires high doses of insulin. Could the additional oral administration of metformin be an option?

  • 78 |
  • 79 |
  • 80 |
  • 81 |
  • 82 |
  • 83 |
  • 84 |
  • 85 |
  • 86 |
  • 87 |
  • 88 |